Part D/Prescription Drugs – Page 49 – medicarereport.org

Friday, September 11, 2026

Latest:

Aging FDA Part D/Prescription Drugs

Eileen Cook June 1, 2023June 1, 2023 FDA, Older Adults, RSV, Vaccines

FDA approves Pfizer’s RSV vaccine for older adults

(By Helen Branswell for ST A T) The Food and Drug Administration approved a second vaccine to protect older adults

Health Care Finance Health Insurance Part D/Prescription Drugs

Eileen Cook May 31, 2023May 31, 2023 Commercial Health Insuranxe, Healthcare Costs, Medicare Part D, Ultra-expensive drugs

Commercial insurance enrollees pay less for ultra-expensive drugs than Medicare Part D members: Study

(By Rylee Wilson for Becker’s Hospital Review ) Medicare Part D beneficiaries that don’t receive low-income subsidies spend 2.5 times

Aging FDA Medicare - General Part D/Prescription Drugs

Eileen Cook May 26, 2023May 26, 2023 FDA, medicare, Older Adults, RSV, Vaccines

Science finally figured out how to make effective RSV vaccines. Will seniors care?

(By Helen Branswell for ST A T) The world has waited decades for vaccines to protect older adults against RSV.

Alzheimer’s/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

Eileen Cook May 25, 2023May 25, 2023 Aduhelm drug, Alzheimer’s Disease, Alzheimer’s Treatment, CMS, FDA, medicare

How Medicare’s Aduhelm decision revived old questions about new drugs

(By Kerry Dooley Young for ST A T) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and

Health Care Finance Health Care Redesign Part D/Prescription Drugs

Eileen Cook May 25, 2023May 25, 2023 Affordable Medicine, Drug-pricing, Healthcare Costs

This Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky

(By Markian Hawryluk for KFF Health News) Catherine Reitzel’s multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies

CMS Medicaid Part D/Prescription Drugs Price Transparency

Eileen Cook May 24, 2023May 24, 2023 CMS, Drug price Transparency, Managed Care plans, Medicaid, PBM

CMS proposes rules to improve Medicaid drug price transparency

(By Rylee Wilson for Becker’s Hospital Review ) CMS is proposing a set of rules for drug manufacturers, pharmaceutical benefit

FTC Legal Actions/Court Decisions Part D/Prescription Drugs

Eileen Cook May 22, 2023May 22, 2023 Drug Companies, Drug costs, FTC, Legal Actions, PBM Industry

A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen

(By Arthur Allen for KFF Health News) Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal

Alzheimer’s/Dementia FDA Health Care Finance Medicare - General Part D/Prescription Drugs

Eileen Cook May 19, 2023May 19, 2023 Alzheimer’s Disease, FDA, Healthcare Finance, Lecanemab Drug, medicare

New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare

(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm

Legislative Update Part D/Prescription Drugs Price Transparency

Eileen Cook May 18, 2023May 18, 2023 340B drug discount program, H.R. 3290, Price Transparency

340B reporting mandate approved by House subcommittee, legislation moves forward

(By Ashleigh Hollowell for Becker’s hospital Review ) Legislation proposing transparency and oversight of the 340B drug discount program was

FDA Health Care Finance Legislative Update Part D/Prescription Drugs

Eileen Cook May 11, 2023 Drug-pricing, Legislation, PBM Industry, pharmaceuticals

PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention

(By Arthur Allen for KFF Health News) For two decades, patients and physicians eagerly awaited a lower-cost version of the